Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C] HMPL-306 in Healthy Chinese Males
NCT06671873Phase 1Completed
- Sponsor
- HUTCHMED
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ranosidenib in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), solid tumor and 1 more, sponsored by HUTCHMED. Primary endpoints: Human Mass Balance, Radioactive Metabolite Profile and 1 more. Started Nov 2024; status: completed.
02
Drugs
ranosidenib
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndromes (MDS)solid tumorglioma
Beyond the preview
Go deeper on NCT06671873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671873.